Precision Neuroscience Appoints Medtech Veterans to Leadership Roles

Precision Neuroscience Corporation has welcomed two senior executives to its top management team. The company hired John Woock, Ph.D., as chief business officer, and named Konstantinos Alataris, Ph.D., to its Board of Directors.

“Adding leaders of John and Konstantinos’s caliber highlights Precision’s momentum as we advance toward commercialization,” Precision Neuroscience Co-Founder/CEO Michael Mager said. “Their track records of building successful neurotechnology businesses are exactly what we need as we plan for scale and widespread impact in coming years.”

The appointments follow Precision Neuroscience’s recent U.S. Food and Drug Administration 510(k) clearance for its high-resolution cortical electrode array that records, monitors, and stimulates electrical activity on the brain’s surface.

Dr. Woock is now in charge of the company’s commercial operations and strategy. Dr. Woock comes from Axonics, a neuromodulation company acquired by Boston Scientific for $3.7 billion in November. As the 15th employee at Axonics, Dr. Woock played a pivotal role in the company’s rapid growth. He was integral to Axonics’ initial product design efforts, headed clinical trials in Europe and the United States, and eventually led the company’s commercial operations, which included a team of more than 500 people. Under Dr. Woock’s leadership, the company launched with more than $110 million in revenue in its first year of U.S. commercial rollout, reaching approximately $450 million in revenue before its acquisition. Prior to Axonics, Dr. Woock was a consultant at McKinsey and a Stanford Biodesign Innovation Fellow. He earned a Ph.D. in biomedical engineering from Duke University.

“Joining Precision at this pivotal point is an incredible opportunity,” Woock stated. “Brain–computer interfaces are one of the most promising medical innovations of our time, and Precision is a clear leader in the field. I look forward to building a commercial operation that supports the immense clinical potential of Precision’s technology.”

Dr. Alataris is a seasoned entrepreneur, investor, and executive with deep experience guiding medtech ventures from inception through commercialization. As founder and CEO of Nevro, Dr. Alataris developed and commercialized the Senza neuromodulation system, revolutionizing treatment for chronic pain. He also chaired the scientific advisory board of Iota Biosciences until it was acquired by Astellas Pharma. Iota is developing implantable devices to treat autoimmune diseases. Dr. Alataris earned a bachelor’s and master’s degree in electrical engineering and computer science, and a Ph.D. in computational neuroscience from the University of Southern California.

“Precision’s differentiated approach and rapid progress in the clinic are bringing AI-enabled therapies for neurological diseases closer to market,” Dr. Alataris said. “This is a testament to the team Ben and Michael have put together. I am thrilled to support Precision in bringing such transformative therapies to patients worldwide.”

Precision Neuroscience is striving to provide breakthrough treatments for neurological illnesses. The company is building the only brain–computer interface designed to be minimally invasive, safely removable, and capable of processing large amounts of data.